




PERSONAL INFORMATION

Milou-Daniel Drici

 Pharmacologie J4 - Hôpital Pasteur 1- 30 avenue de la Voie Romaine-CS 51069, 06001 Nice cedex 1 (France)
 (+33)492038502
 drici.md@chu-nice.fr

WORK EXPERIENCE

-
- 2003–Present **Chief of Department and Chair, Pharmacology**
University of Nice Medical Center, Nice (France)
- 2003–Present **Professor of Clinical Pharmacology**
University of Nice, Nice (France)
- 2010–Present **Head of Regional Pharmacovigilance Center of Nice-Alpes-Côte d'Azur (2.3 millions inhabitants)**
Nice University Medical Center- Health Regional Agency, Nice (France)
- 2010–Present **Co-opted Member of the SAG Cardio**
European Medicines Agency, London (United Kingdom)
- 2013–Present **President, IUPHAR Subcommittee of Pharmacovigilance-Pharmacoepidemiology**
IUPHAR, Kansas City, KS (United States)
- 2015–Present **Board Member of Credible Meds for QT drugs/DTA lists**
AZCERT Inc, Oro Valley, AZ (United States)
- 2000–Present **External Expert (CNS, cancer, AB and antiviral drugs)**
French national agency of drug safety ANSM, Saint Denis (France)
- 2000–Present **ASNM Working Groups member : Clinical trials (2000-2010), Cardio-thrombosis (2003-present), pharmacovigilance (2008-present)**
French national agency of drug safety ANSM, Saint Denis (France)
- 1993–2003 **Associate Professor of Clinical Pharmacology**
University of Nice, Nice (France)
- 1989–1993 **Assistant Professor in Clinical Pharmacology**
University of Nice School of Medicine, Nice (France)
- 1982–1989 **Resident in Cardiology and Clinical Pharmacology**
Nice and Paris University Hospitals, Nice, Paris (France)

EDUCATION AND TRAINING

- 03/11/2013–09/11/2013 **Epidemiologic Principles and Methods**
KJ Rothman & EE Hatch - Faculty of Medicine A. Gemelli, Rome (Italy)
- 01/01/1995–30/04/1997 **International Merck Fellowship in Clinical Pharmacology (laureate)**
Georgetown University, Washington DC (United States)
- 1993 **Ph. D. in Clinical Pharmacology**
University of Aix-Marseille School of Pharmacy, Marseille (France)
- 1989 **Cardiology and Vascular Diseases board certification**
- 1989 **M.D.**
University of Nice, Nice (France)
- 01/01/1995–30/04/1997 **Internal Reviewing Courses : Topics in Clinical Trials - Clinical Pharmacokinetics - Basic Statistical Methods -**
Food and Drugs Administration, Rockville, MD (United States)

PERSONAL SKILLS

Mother tongue(s) French

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C1	C2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages

ADDITIONAL INFORMATION

- Memberships**
- IUPHAR : International Union of Pharmacology (US).
 - Fellow of the European Society of Cardiology (EU)
 - Cardiac Muscle Society (US)
 - Cardiac Rhythm Society (US)
 - British Pharmacology Society (UK)
 - French Society of Pharmacology and Therapeutics (FR)
 - French Society of Cardiology (FR)
 - French Society of Hypertension (FR)

- Publications**
1. Quintard H, Viard D, Drici MD, Ruetsch C, Samama CM, Ichai C. Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding. *Thromb Haemost.* 2017;117(1):196-7.
 2. Lagneau A, Vigier C, Marianna A, Serfaty R, Rocher F, Spreux A, Drici MD. Comparative relevance of declaration of side effects by patients and health professionals. *Therapie.* 2017.

3. Gicquel C, Moulis F, Chenaf C, Gouraud A, Drici M, Bondon-Guitton E, Montastruc F, Montastruc JL. Duloxetine and gingival bleeding: a case-report and reviews of the French and World Pharmacovigilance Databases and literature. *Eur J Clin Pharmacol*. 2017;73(9):1197-8.
4. Steve-Dumont M, Baldin B, Legros L, Thyss A, Re D, Rocher F, Ajmia F, Spreux A, Drici MD. Are nilotinib-associated vascular adverse events an under-estimated problem? *Fundam Clin Pharmacol*. 2015;29(2):204-8.
5. Drici MD, Baldin B. Is the clinical development of drugs appropriate in the elderly population? *Rev Prat*. 2015;65(5):602-4.
6. Bardy G, Fischer F, Appert A, Baldin B, Steve M, Spreux A, Lavrut T, Drici MD. Is anti-factor Xa chromogenic assay for Rivaroxaban appropriate in clinical practice? Advantages and comparative drawbacks. *Thromb Res*. 2015;136(2):396-401.
7. Tuppin P, Cuerq A, de Peretti C, Fagot-Campagna A, Danchin N, Juilliere Y, Alla F, Allemand H, Bauters C, Drici MD, Hagege A, Jondeau G, Jourdain P, Leizorovicz A, Paccaud F. Two-year outcome of patients after a first hospitalization for heart failure: A national observational study. *Arch Cardiovasc Dis*. 2014;107(3):158-68.
8. Hajj A, Ksouda K, Peoc'h K, Curis E, Messali A, Deveaux LL, Bloch V, Prince N, Mouly S, Schermann JM, Lepine JP, Laplanche JL, Drici MD, Vorspan F. KCNH2 polymorphism and methadone dosage interact to enhance QT duration. *Drug Alcohol Depend*. 2014;141:34-8.
9. Tuppin P, Cuerq A, de Peretti C, Fagot-Campagna A, Danchin N, Juilliere Y, Alla F, Allemand H, Bauters C, Drici MD, Hagege A, Jondeau G, Jourdain P, Leizorovicz A, Paccaud F. First hospitalization for heart failure in France in 2009: patient characteristics and 30-day follow-up. *Arch Cardiovasc Dis*. 2013;106(11):570-85.
10. Menard ML, Yagoubi F, Drici M, Lavrut T, Askenazy F. Follow-up of a 16-year-old adolescent with early-onset schizophrenia and catatonic symptoms. *Encephale*. 2013;39 Suppl 1:S29-35.
11. Darini CY, Martin P, Azoulay S, Drici MD, Hofman P, Obba S, Dani C, Ladoux A. Targeting cancer stem cells expressing an embryonic signature with anti-proteases to decrease their tumor potential. *Cell Death Dis*. 2013;4:e706.
12. Mialon O, Delotte J, Lehert P, Donzeau M, Drici M, Isnard V, Bongain A. Comparison between two analgesic protocols on IVF success rates. *J Gynecol Obstet Biol Reprod (Paris)*. 2011;40(2):137-43.
13. Marti J, Lachaud S, Rocher F, Drici MD. Partial seizure during treatment with interferon alpha for chronic hepatitis C virus. *Therapie*. 2011;66(2):179-82.
14. Thomas SH, Drici MD, Hall GC, Crocq MA, Everitt B, Lader MH, Le Jeunne C, Naber D, Priori S, Sturkenboom M, Thibaut F, Peuskens J, Mittoux A, Tanghoj P, Toumi M, Moore ND, Mann RD. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). *Acta Psychiatr Scand*. 2010;122(5):345-55.
15. Crocq MA, Naber D, Lader MH, Thibaut F, Drici M, Everitt B, Hall GC, Le Jeunne C, Mittoux A, Peuskens J, Priori S, Sturkenboom M, Thomas SH, Tanghoj P, Toumi M, Mann R, Moore ND. Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. *Eur Neuropsychopharmacol*. 2010;20(12):829-38.
16. Drici MD. New antiarrhythmic drugs for atrial fibrillation. *Ann Cardiol Angeiol (Paris)*. 2009;58 Suppl 1:S61-3.
17. Djedaini M, Peraldi P, Drici MD, Darini C, Saint-Marc P, Dani C, Ladoux A. Lopinavir co-induces insulin resistance and ER stress in human adipocytes. *Biochem Biophys Res Commun*. 2009;386(1):96-100.
18. Drici MD, Priori S. Cardiovascular risks of atypical antipsychotic drug treatment. *Pharmacoepidemiol Drug Saf*. 2007;16(8):882-90.
19. ourrinet P, Martel E, El Amrani AI, Champeroux P, Richard S, Fauchou N, Le Coz F, Drici M, Bonnemain B, Gaillard S. Cardiovascular safety of gadoterate meglumine (Gd-DOTA). *Invest Radiol*. 2007;42(2):63-77.
20. Ambrosi P, Drici MD, Herpin D, Pathak A. The best of clinical pharmacology in 2006. *Arch Mal Coeur Vaiss*. 2007;100 Spec No 1:99-102.
21. Ambrosi R, Andrejak M, Drici MD, Herpin D, Groupe de Pharmacologie Clinique et Therapeutique de la SFC. The best of clinical cardiovascular pharmacology in 2005. *Arch Mal Coeur Vaiss*. 2006;99 Spec No 1(1):95-9.
22. Liu T, Choi BR, Drici MD, Salama G. Sex modulates the arrhythmogenic substrate in prepubertal rabbit hearts with Long QT 2. *J Cardiovasc Electrophysiol*. 2005;16(5):516-24.
23. Leo F, Venissac N, Drici MD, Mouroux J. Aluminium and primary spontaneous pneumothorax. A

- suggestive but unconfirmed hypothesis. *Interact Cardiovasc Thorac Surg*. 2005;4(1):21-2.
24. Ambrosi P, Andrejak M, Drici MD, Herpin D, Pithois-Merli I, Groupe de pharmacologie clinique et thérapeutique de la SFC. The best of clinical pharmacology in 2004. *Arch Mal Coeur Vaiss*. 2005;98 Spec No 1:51-5.
25. Drici MD, Baker L, Plan P, Barhanin J, Romey G, Salama G. Mice display sex differences in halothane-induced polymorphic ventricular tachycardia. *Circulation*. 2002;106(4):497-503.
26. Drici MD, Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. *Drug Saf*. 2001;24(8):575-85.
27. Arrighi I, Bloch-Faure M, Grahammer F, Bleich M, Warth R, Mengual R, Drici MD, Barhanin J, Meneton P. Altered potassium balance and aldosterone secretion in a mouse model of human congenital long QT syndrome. *Proc Natl Acad Sci U S A*. 2001;98(15):8792-7.
28. Flockhart DA, Drici MD, Kerbusch T, Soukhova N, Richard E, Pearle PL, Mahal SK, Babb VJ. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. *J Clin Psychopharmacol*. 2000;20(3):317-24.
29. Drici MD, Diochot S, Terrenoire C, Romey G, Lazdunski M. The bee venom peptide tertiapin underlines the role of I(KACh) in acetylcholine-induced atrioventricular blocks. *Br J Pharmacol*. 2000;131(3):569-77.
30. Drici MD, Barhanin J. Cardiac K⁺ channels and drug-acquired long QT syndrome. *Therapie*. 2000;55(1):185-93.
31. Chouabe C, Neyroud N, Richard P, Denjoy I, Hainque B, Romey G, Drici MD, Guicheney P, Barhanin J. Novel mutations in KvLQT1 that affect I_{Ks} activation through interactions with Isk. *Cardiovasc Res*. 2000;45(4):971-80.
32. Chouabe C, Drici MD, Romey G, Barhanin J. Effects of calcium channel blockers on cloned cardiac K⁺ channels IKr and IKs. *Therapie*. 2000;55(1):195-202.
33. Drici MD, Ebert SN, Wang WX, Rodriguez I, Liu XK, Whitfield BH, Woosley RL. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. *J Cardiovasc Pharmacol*. 1999;34(1):82-8.
34. Diochot S, Drici MD, Moinier D, Fink M, Lazdunski M. Effects of phrixotoxins on the Kv4 family of potassium channels and implications for the role of Ito1 in cardiac electrogenesis. *Br J Pharmacol*. 1999;126(1):251-63.
35. Wang WX, Ebert SN, Liu XK, Chen YW, Drici MD, Woosley RL. "Conventional" antihistamines slow cardiac repolarization in isolated perfused (Langendorff) feline hearts. *J Cardiovasc Pharmacol*. 1998;32(1):123-8.
36. Liu XK, Katchman A, Drici MD, Ebert SN, Ducic I, Morad M, Woosley RL. Gender difference in the cycle length-dependent QT and potassium currents in rabbits. *J Pharmacol Exp Ther*. 1998;285(2):672-9.
37. Drici MD, Wang WX, Liu XK, Woosley RL, Flockhart DA. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. *J Clin Psychopharmacol*. 1998;18(6):477-81.
38. Drici MD, Knollmann BC, Wang WX, Woosley RL. Cardiac actions of erythromycin: influence of female sex. *JAMA*. 1998;280(20):1774-6.
39. Drici MD, Arrighi I, Chouabe C, Mann JR, Lazdunski M, Romey G, Barhanin J. Involvement of Isk-associated K⁺ channel in heart rate control of repolarization in a murine engineered model of Jervell and Lange-Nielsen syndrome. *Circ Res*. 1998;83(1):95-102.
40. Chouabe C, Drici MD, Romey G, Barhanin J, Lazdunski M. HERG and KvLQT1/IsK, the cardiac K⁺ channels involved in long QT syndromes, are targets for calcium channel blockers. *Mol Pharmacol*. 1998;54(4):695-703.
41. Raucoules-Aime M, Drici M, Goubaux B, Labib Y, Ichai C, Gugenheim J, Grimaud D. Intravenous nicardipine does not alter hepatic blood flow after orthotopic liver transplant. *Intensive Care Med*. 1996;22(5):420-5.
42. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. *Circulation*. 1996;94(6):1471-4.
43. Drici MD, Raybaud F, De Lunardo C, Iacono P, Gustovic P. Influence of the behaviour pattern on the placebo response of healthy volunteers. *Br J Clin Pharmacol*. 1995;39(2):204-6.
44. Andrejak M, Mallion JM, Asmar R, Chau NG, de Gaudemaris R, Drici M, Herpin D, Poncelet P. Ambulatory blood pressure monitoring and clinical trials. *Arch Mal Coeur Vaiss*. 1995;88(8):1175-8.
45. Hofman P, Drici MD, Gibelin P, Michiels JF, Thyss A. Prevalence of toxoplasma myocarditis in

- patients with the acquired immunodeficiency syndrome. *Br Heart J.* 1993;70(4):376-81.
46. Drici MD, Raucoules M, Jacomet Y, Iacono P, Ichai C, Grimaud D, Lapalus P. Clinical pharmacology of nicardipine in liver transplant patients. *Fundam Clin Pharmacol.* 1993;7(9):531-6.
47. Drici MD, Jacomet Y, Iacono P, Lapalus P. Is verapamil also a non-selective beta blocker? *Int J Clin Pharmacol Ther Toxicol.* 1993;31(1):27-30.
48. Candito M, Pringuey D, Lehert P, Drici M, Souetre E, Chambon P, Darcourt G. 5-Methoxypsoralen: effect on the noradrenaline circadian rhythm of sleep-deprived subjects. *Life Sci.* 1993;53(22):PL355-8.
49. Lapalus P, Drici MD, Iacono P. Clinical benefit of slow calcium channel antagonists in cerebral ischaemia. *Clin Neuropharmacol.* 1992;15 Suppl 1 Pt A:134A.
50. Lapalus P, Denis P, Drici M, Fredj-Reygrobellet D, Elena PP. Retinal dopaminergic receptor affinity and ocular pharmacokinetic profile of pibedil. *J Neurol.* 1992;239 Suppl 1:S17-21.
51. Iacono P, Drici MD, De Lunardo C, Salimbeni B, Lapalus P. Placebo effect in cardiovascular clinical pharmacology. *Int J Clin Pharmacol Res.* 1992;12(2):53-6.
52. Gibelin P, Bossan P, Ferrari E, Drici M, Morand P. Treatment of chronic heart insufficiency with dobutamine. Value and limitations. *Presse Med.* 1992;21(35):1680-4.
53. Drici MD, Cocoz F, Morand P, Lapalus P. Evaluation of anti-atheromatous properties of calcium channel inhibitors. *Arch Mal Coeur Vaiss.* 1992;85 Spec No 2:161-5.
54. Ferrari E, Taillan B, Drici M, Peuchot N, Proton A, Leonetti J. Thrombocytopenia induced by treatment with furosemide. *Presse Med.* 1991;20(8):385.
55. Drici MD, Teboul B, Lapalus P, Morand P, Atlan JP, Bouche JM, Ceccaldi JP, Giacomoni S, Halimi G, Passeron-Seitre M, et al. Comparative efficacy of sustained release verapamil and captopril in mild to moderate arterial hypertension by ambulatory measurement and occasional measurement. *Ann Cardiol Angeiol (Paris).* 1991;40(9):567-70.
56. Drici MD, Roux M, Candito M, Rimalho A, Morand P, Lapalus P. Influence of beta-blockade on circulating plasma levels of 3-methoxy-4-hydroxy phenylethylene glycol (MHPG) during exercise in moderate hypertension. *Clin Exp Pharmacol Physiol.* 1991;18(12):807-11.
57. Drici MD, Morand P, Lapalus P. Lack of placebo effect in exercise response of hypertensive patients. *Int J Clin Pharmacol Ther Toxicol.* 1991;29(1):38-41.
58. Drici MD, Candito M, Ferrari E, Jacomet Y, Morand P, Lapalus P. Clinical and biological evaluation of dilevalol vasodilating properties in mild to moderate hypertension. *Int J Clin Pharmacol Ther Toxicol.* 1991;29(9):361-5.
59. Dallochio M, Gosse P, Fillastre JP, Grollier G, Morand P, Drici M, Corcoran C. Rilmenidine, a new antihypertensive agent in the first line treatment of essential arterial hypertension. Multicenter double-blind study versus atenolol. *Presse Med.* 1991;20(27):1265-71.
60. Gibelin P, Sbirrazzuoli V, Drici M, Camous JP, Lapalus P, Morand P. Effects of short-term administration of dobutamine on left ventricular performance, exercise capacity, norepinephrine levels, and lymphocyte adrenergic receptor density in congestive heart failure. *Cardiovasc Drugs Ther.* 1990;4(4):1105-11.
61. Gibelin P, Sbirrazzuoli V, Drici M, Bossan P, Baudouy M, Lapalus P, Morand P. Role of myocardial beta-adrenergic receptors in cardiac insufficiency. *Ann Cardiol Angeiol (Paris).* 1990;39(3):165-71.
62. Drici MD, Roux M, Ferrari E, Lapalus P, Morand P. Evaluation of the placebo effect on blood pressure profile during exercise in patients with mild uncomplicated hypertension. *Arch Mal Coeur Vaiss.* 1990;83(8):1111-4.
63. Drici MD. Alpha-1 inhibition and blood pressure regulation. *Ann Cardiol Angeiol (Paris).* 1990;39(10 (Pt 2)):629-30.
64. Sbirrazzuoli V, Drici M, Garraffo R, Candito M, Gibelin P, Morand P, Lapalus P. Changes in lymphocyte beta-adrenoceptor density after dilevalol oral treatment. *Drugs Exp Clin Res.* 1989;15(5):223-9.
65. Jaillon P, Drici M. Recent antiarrhythmic drugs. *Am J Cardiol.* 1989;64(20):65J-9J.
66. Ferrari E, Fournier JP, Gibelin P, Drici MD, Morand P. Is treatment with molar lactate in flecainide poisoning safe? *Presse Med.* 1989;18(28):1395.
67. Drici MD, Sbirrazzuoli V, Garraffo R, Wajman A, Morand P, Lapalus P. Effect of propafenone hydrochloride on lymphocyte membrane beta 2 adrenoceptors in ventricular arrhythmias. *Am J Cardiol.* 1989;64(10):671-4.
68. Gibelin P, Lloret JL, Drici M, Leborgne L, Camous JP, Melia P, Morand P. Treatment of chronic

cardiac failure with cadralazine. Short- and medium-term results. Arch Mal Coeur Vaiss. 1987;80(2):199-205.

Book chapters

69. Drici MD, Roden DM. Drug-Induced Sudden death. Sudden Cardiac Death. In: Priori S.G., MS, USA, editor. Blackwell Publishing 2006. p. 177-85.
70. Barhanin J, Drici MD. Cardiac K⁺ channels and inherited long QT syndrome. In: M. Endo MM, Y. Kurachi Heidelberg, Germany ; Springer-Verlag GmbH & Co. KG, editor. Pharmacology of ionic channel function. Handbook of Experimental Pharmacology. 2000 . Vol 147. p. 347-62.
71. Escande D, Drici MD Barhanin J. Molecular pathophysiology of cardiomyopathies. In: N. Sperelakis YK, A. Terzic, M.V. Cohen, San Diego, CA-USA ; Academic Press, editor. 4th ed 2000. p. 1097-105.
72. Flockhart DA, Drici MD. Nitroprusside, ACE inhibitors, and selected antihypertensive agents. In: Haddad S, Winchester, editor. Clinical Management of poisoning and drug overdose. 3rd ed 1997. p. 1041-7.
73. Drici MD, Woosley RL. Drug and metabolic factors in sudden death. In: Sudden Cardiac Death : Past Present and Future Sudden Cardiac Death : Past, Present, and Future, editor. 1997. p. 75-84.